Jinling Pharmaceutical Company Limited (SHE:000919)

SHE:000919 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	-	1,517	1,771	1,548	1,495	1,502
Short-Term Investments	-	393.03	165.22	337.45	250	-
Trading Asset Securities	-	939.31	706.05	233.86	92.35	1.25
Cash & Short-Term Investments	2,766	2,849	2,642	2,119	1,837	1,503
Cash Growth	3.83%	7.84%	24.69%	15.33%	22.25%	14.12%
Accounts Receivable	-	690.95	686.73	591.05	467.22	507.2
Other Receivables	-	13.79	8.16	8.76	53.12	16.85
Receivables	-	704.74	694.89	599.81	520.34	524.05
Inventory	-	233.14	271.62	290.91	250.48	245.48
Prepaid Expenses	-	-	-	0.15	1.16	-
Other Current Assets	-	10.52	9.37	9.63	23.79	16.29
Total Current Assets	-	3,798	3,618	3,020	2,633	2,289
Property, Plant & Equipment	-	1,457	1,501	1,541	1,303	1,297
Long-Term Investments	-	211.37	431.07	369.32	265.01	638.97
Goodwill	-	44.37	62.42	148.72	27.33	18.05
Other Intangible Assets	-	322.93	325.67	341.67	258.44	140.2
Long-Term Deferred Tax Assets	-	12.61	12.49	16.61	28.54	19.62
Long-Term Deferred Charges	-	120.55	83.34	13.94	18.26	17.85
Other Long-Term Assets	-	40.31	54.49	42	10.7	26.96
Total Assets	-	6,007	6,089	5,493	4,544	4,448

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	-	554.97	595.31	546.69	454.04	479.36
Accrued Expenses	-	222.28	212.46	224.73	219.95	207.27
Short-Term Debt	-	-	-	-	1.48	15.01
Current Portion of Leases	-	8.74	4.23	3.08	1.53	1.06
Current Income Taxes Payable	-	32.37	35.53	37.97	48.38	43.09
Current Unearned Revenue	-	19.57	35.6	17.65	22.14	26.9
Other Current Liabilities	-	138.03	143.9	182.53	117.9	83.25
Total Current Liabilities	-	975.95	1,027	1,013	865.42	855.95
Long-Term Debt	-	150.1	150.12	-	-	-
Long-Term Leases	-	32.98	34.85	38.6	2.29	0.59
Long-Term Unearned Revenue	-	0.68	1	0.47	0.63	0.79
Long-Term Deferred Tax Liabilities	-	25.01	27.28	28.72	48.98	55.77
Total Liabilities	-	1,185	1,240	1,080	917.32	913.1

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	-	621.92	623.71	511.14	510.4	504
Additional Paid-In Capital	-	1,088	1,098	651.74	478.34	462.06
Retained Earnings	-	2,065	2,073	2,095	2,025	1,958
Treasury Stock	-	-	-6.77	-26.99	-23.62	-
Comprehensive Income & Other	-	2.66	3.09	3.42	4.17	3.29
Total Common Equity	3,806	3,778	3,791	3,234	2,994	2,928
Minority Interest	-	1,044	1,057	1,178	632.88	606.84
Shareholders' Equity	4,852	4,822	4,849	4,412	3,627	3,535
Total Liabilities & Equity	-	6,007	6,089	5,493	4,544	4,448

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	192.17	191.82	189.21	41.67	5.3	16.66
Net Cash (Debt)	2,574	2,658	2,453	2,077	1,832	1,486
Net Cash Growth	4.03%	8.34%	18.08%	13.39%	23.26%	12.85%
Net Cash Per Share	4.14	4.27	4.14	4.12	3.64	2.95
Filing Date Shares Outstanding	621.72	621.92	623.71	629.06	488.88	510.4
Total Common Shares Outstanding	621.72	621.92	623.71	511.14	488.88	504
Working Capital	-	2,822	2,591	2,007	1,768	1,433
Book Value Per Share	6.12	6.07	6.08	6.33	6.12	5.81
Tangible Book Value	3,444	3,410	3,403	2,744	2,708	2,769
Tangible Book Value Per Share	5.54	5.48	5.46	5.37	5.54	5.50
Buildings	-	1,510	1,495	1,507	1,294	1,274
Machinery	-	1,498	1,416	1,349	1,114	1,074
Construction In Progress	-	48.16	71.78	84.2	37.84	28.78

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error